MitraClip for the Treatment of Moderate Functional Mitral Regurgitation: EVOLVE-MR

A trial with no phase registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 174 participants.

Also called NCT03705312

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 174 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT03705312
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Canada (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT03705312. Randomized; single masking; primary purpose treatment. Start 2019-02-22 (actual); primary completion 2021-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
MitraClip for the Treatment of Moderate Functional Mitral Regurgitation: EVOLVE-MR
Acronym
EVOLVE-MR
Condition
Mitral Regurgitation
Condition
Heart Failure
Condition
Mitral Valve Regurgitation Due to Cardiomyopathy (Disorder)
Intervention (Device)
Transcatheter mitral valve repair
Intervention (Other)
Guideline-directed medical therapy
Lead sponsor
Montreal Heart Institute (class: other)
Collaborator
Abbott Medical Devices (class: industry)

Record details

Record id
cardio:ct-nct03705312
Content hash
613acca208a752bc4b55d0ece9a387ffc6eebd26d63c4c2a72be53b2412d170b